I'm confused. The company seems to have always maintained over the years the Board's desire to go it alone, but taking on partnerships for needed financial support on specific clinical initiatives, suggesting a variety of potential partners over the future. Lasers is suggesting the company already has authorization/ability for the issuance of sufficient preferred shares for a partnership. Why doesn't that route negate the need for the proxy,additional 'new' shares and apparently the potential for further dilution?
But just a question? What could be better for ACTC? to issue preferred shares for new partner and go through all the phases of until the approval?
OR Keep their financial difficulties and take more time before reach the FDA approval?
I perfectly understand your point under the dilution but could it be good if that partner allows ACTC to reach their market with their stem cells therapy and cure blindness?
News 
Market Data 
Discover 
